表观遗传年龄加速与衰弱及持续性ADL残疾风险
本研究纳入560名70岁以上澳大利亚人,基线检测七种表观遗传年龄加速指标,随访7年。发现GrimAge、GrimAge2、FitAge和DunedinPACE加速与衰弱指数评分逐年增加相关,GrimAge和GrimAge2加速与衰弱发生风险增加相关,未发现与持续性ADL残疾相关。
要点
- GrimAge、GrimAge2、FitAge和DunedinPACE加速与衰弱指数评分逐年增加相关。
- GrimAge和GrimAge2加速与衰弱发生风险增加相关(校正HR分别为1.43和1.39)。
- 未发现表观遗传年龄加速与持续性ADL残疾相关。
核心结论
- 晚年表观遗传年龄加速与衰弱指数评分逐年增加及衰弱发生风险相关,但与持续性ADL残疾无关。
研究设计与样本
- 研究纳入560名年龄≥70岁的澳大利亚人(女性占50.7%),随访7年。
- 基线通过外周血DNA甲基化估计七种表观遗传年龄加速指标,包括GrimAge、GrimAge2、FitAge和DunedinPACE。
- 衰弱采用67项缺陷累积衰弱指数和Fried表型评估,持续性ADL残疾定义为基本ADL能力丧失至少6个月。
- 使用线性混合模型和Cox比例风险回归模型分析。
主要发现
- 基线GrimAge、GrimAge2、FitAge和DunedinPACE加速与衰弱指数评分每年增加相关(校正Beta范围0.0015至0.0021,P<0.05)。
- 基线GrimAge和GrimAge2加速与衰弱指数定义的衰弱发生风险增加相关(校正HR分别为1.43和1.39,P<0.05)。
- DunedinPACE与衰弱指数评分变化的关联在女性中更强(校正Beta 0.0029,P=0.001) than 男性(校正Beta 0.0002,P=0.81)。
- DunedinPACE与Fried评分恶化相关(校正Beta 0.0175,P=0.04),其他表观遗传年龄加速指标未显示该关联。
- 未观察到表观遗传年龄加速与持续性ADL残疾的关联。
关键数值与推荐
- GrimAge和GrimAge2加速与衰弱指数定义衰弱发生风险的校正HR分别为1.43和1.39(P<0.05)。
- GrimAge、GrimAge2、FitAge和DunedinPACE加速与衰弱指数评分每年增加的校正Beta范围为0.0015至0.0021(P<0.05)。
- DunedinPACE与衰弱指数评分变化的校正Beta在女性为0.0029(P=0.001),男性为0.0002(P=0.81)。
- DunedinPACE与Fried评分恶化的校正Beta为0.0175(P=0.04)。
临床怎么用
- 表观遗传年龄加速指标可作为晚年衰弱风险分层的潜在生物标志物。
- GrimAge和GrimAge2加速提示衰弱发生风险增加,可辅助识别高危老年人。
- DunedinPACE与女性衰弱指数评分增加关联更强,提示性别差异。
- 表观遗传年龄加速未显示与持续性ADL残疾相关,不宜单独用于预测ADL残疾。
局限性
- 原文未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Epigenetic ageing is among the most promising ageing biomarkers and may be a useful marker of physical function decline, beyond chronological age. This study investigated whether epigenetic age acceleration (AA) is associated with the change in frailty scores over 7 years and the 7-year risk of incident frailty and persistent Activities of Daily Living (ADL) disability among 560 Australians (50.7% females) aged ≥70 years. METHODS: Seven AA indices, including GrimAge, GrimAge2, FitAge and DunedinPACE, were estimated from baseline peripheral-blood DNA-methylation. Frailty was assessed using both the 67-item deficit-accumulation frailty index (FI) and Fried phenotype (Fried). Persistent ADL disability was defined as loss of ability to perform one or more basic ADLs for at least 6 months. Linear mixed models and Cox proportional-hazard regression models were used as appropriate. RESULTS: Accelerated GrimAge, GrimAge2, FitAge and DunedinPACE at baseline were associated with increasing FI scores per year (adjusted-Beta ranged from 0.0015 to 0.0021, P < 0.05), and accelerated GrimAge and GrimAge2 were associated with an increased risk of incident FI-defined frailty (adjusted-HRs 1.43 and 1.39, respectively, P < 0.05). The association between DunedinPACE and the change in FI scores was stronger in females (adjusted-Beta 0.0029, P 0.001 than in males (adjusted-Beta 0.0002, P 0.81). DunedinPACE, but not the other AA measures, was also associated with worsening Fried scores (adjusted-Beta 0.0175, P 0.04). No associations were observed with persistent ADL disability. CONCLUSION: Epigenetic AA in later life is associated with increasing frailty scores per year and the risk of incident FI-defined frailty.
引用
- Phyo AZZ, Espinoza SE, Murray AM, et al. Epigenetic age acceleration and the risk of frailty, and persistent activities of daily living (ADL) disability. Age Ageing. 2024. PMID: 38941117. doi:10.1093/ageing/afae127
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。